At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 48 enrolled
Drug / intervention
ALXN1840drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, 2-period, 2-sequence, Crossover With Parallel-group Extension, Open-label Study to Compare the Relative Bioavailability of 2 Oral Formulations of ALXN1840 in Healthy Adult Participants
In Brief
A Phase 1 clinical trial evaluating ALXN1840 for Healthy. Completed, enrolled 48 participants across 1 site.
Detailed Summary
The study will assess the relative bioavailability of 2 different formulations of ALXN1840 in healthy participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesAustralia
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartJan 2021
Primary CompletionMar 2021
Study CompletionApr 2021
TodayJul 2026
First PostedOct 30, 2020
Enrollment StartJan 31, 2021
Primary CompletionMar 24, 2021
Study CompletionApr 26, 2021
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 5.7 years ago
Interventions
ALXN1840drug
ALXN1840 will be administered orally.